期刊
CANCER LETTERS
卷 316, 期 2, 页码 178-186出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.10.033
关键词
Pancreatic neoplasia; GSK-3 beta; RNA interference; Molecular targeted therapy
类别
资金
- National Nature Science Foundation of China [30801098, 30972903]
Glycogen synthase kinase-3 beta (GSK-3 beta), a serine/threonine protein kinase, plays a vital role in the tumorigenesis of many cancers, but its role in pancreatic cancer remains unknown. In this study, we showed that GSK-3 beta was aberrantly activated in pancreatic cancer. GSK-3 beta knockdown resulted in arrested proliferation and increased apoptosis in pancreatic cancer cell lines. Expression of Bcl-2 and vascular endothelial growth factor (VEGF) decreased significantly in a GSK-3 beta knockdown group. In a xenograft tumor model, GSK-3 beta knockdown inhibited tumor growth and angiogenesis. Our study showed that GSK-3 beta may become a promising therapeutic target for human pancreatic cancer. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据